Enterprise Europe Network (Profile:TRCN20181019004)
A Chinese genetic disease and oncogene detection company is looking for technologies to detect bladder cancer. A non-invasive detection, only using blood or urine, is sought, and with no surgery or puncture biopsy required, while achieving tissue detection sensitivity and specificity.
They want to cooperate with partners through research cooperation agreement and technical cooperation agreement.
The company which established in 2014, is located in Changsha City, Hunan Province.
The company dedicates to develop genetic disease and oncogene detection, and develop world-class biochip, providing genetic information big data and health management solutions. Founded in 2014, the company's main products (services) include susceptible, non-invasive oncogene detection, biological computing, big data management and gene chip.
Traditionally, it usually uses tissue specimens for detection (biopsy), but there are certain limitations in tissue specimen detection, such as the inability of taking surgical samples from patients in late stage, poor tolerance to repeat biopsy, and heterogeneity of tumor tissues.
The company wonders if there is non-invasive detection (only use blood or urine, and no surgery or puncture biopsy is required), while achieving tissue detection sensitivity and specificity.
They are looking for a technology to detect bladder cancer.
They want to cooperate with partners through research cooperation agreement and technical cooperation agreement， buying either existing technologies for adaptation into detection, or research into ways to development the bladder cancer detection.
For more information please contact Enterprise Europe Network Latvia.